Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Ankylosing Spondylitis Treatment Study

Clinical Trial Title: 
A randomized, double-blind, parallel group, multicenter study to compare secukinumab at 300 mg and 150 mg in patients with ankylosing spondylitis (AS).
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Joel Block, MD
Clinical Trial Protocol Description: 

The purpose of this 52 week study is to estimate the difference in clinical response between 300 mg and 150 mg of secukinumab after a 16 week baseline dose of 150 mg. This study will also investigate the association between treatment and sleep disturbance as well as daytime activity patterns.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are at least 18 years of age.
  • Have a diagnosis of moderate to severe AS with prior documented radiologic evidence (X-ray or radiologists report) fulfilling the modified New York criteria for AS.

You will be excluded from the study if any of the following criteria apply to you:

  • Have total ankylosis of the spine.
  • Have a history of hypersensitivity to any of the study drugs.
  • Have a history of other significant inflammatory autoimmune disease, lymphoproliferative disease or any malignancy.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Arthritis and Other Rheumatic Diseases
Contact Phone: 
(312) 563-2955
Contact Name: 
Joshlean Fair